Ranitidine CAS: 66357-35-5
MF: C13H22N4O3S
MW: 314.41
A selective and competitive histamine H2 receptor inhibitor.

Ranitidine (CAS 66357-35-5)

Ranitidine | CAS 66357-35-5 is rated 5.0 out of 5 by 1.
  • y_2020, m_2, d_22, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203679, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 142ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: N-[2-[[[5-[(Dimethylamino)methyl]-2 -furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethanediamine
Application: A selective and competitive histamine H2 receptor inhibitor
CAS Number: 66357-35-5
Purity: ≥95%
Molecular Weight: 314.41
Molecular Formula: C13H22N4O3S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Ranitidine is a potent, selective and competitive histamine H2 receptor inhibitor which mediates gastric secretion.

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in water.
Storage :
Desiccate at 4° C
Melting Point :
69-72° C
Boiling Point :
~437.13° C at 760 mmHg (Predicted)
Density :
~1.18 g/cm3 (Predicted)
Refractive Index :
n20D 1.56 (Predicted)
pK Values :
pKb: 8.36 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
RTECS :
KM6556500
PubChem CID :
3001055
Merck Index :
14: 8110
MDL Number :
MFCD00081180
EC Number :
266-332-5
Beilstein Registry :
4327819
SMILES :
CN/C(=C\\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

What exactly and in layman/'s terms does "mediates gastric secretion" mean?

Asked by: Shad
Thank you for you question. Ranitidine is a potent, selective and competitive histamine H2 receptor inhibitor which mediates gastric secretion, which means this biochemical is involved in mediating stomach secretions. This product is for research use only.
Answered by: Tech Service
Date published: 2019-01-14
  • y_2020, m_2, d_22, h_18CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_203679, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 149ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Shi Shi, H. et al. (PubMed 26064051) reported that the H2R inhibitor Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats. -SCBT Publication Review
Date published: 2015-01-24
  • y_2020, m_2, d_22, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203679, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 21ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.